Powered by

Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease

Jan 31, 2019 - Thomson Reuters ONE

Discontinued crenezumab phase 3 studies underscore urgent need for therapies that target the toxic oligomer with extraordinary precision

TORONTO and CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, highlights the urgent need to selectively target the toxic oli...